Pocket Program - CROI

Poster Listings
Session 180 CROI 2013
975a Is Nevirapine Dose Escalation Appropriate in Young African
HIV + Children?
Quirine Fillekes* 1 , V Mulenga2 , D Kabamba2 , C Kankasa2 ,
M Thomason3 , A Cook3 , C Chintu2 , D Gibb3 , S Walker3 , and D Burger1 1 2 Radboud Univ Nijmegen Med Ctr, The Netherlands;; Univ Teaching
Hosp, Lusaka, Zambia;; and 3MRC Clinical Trials Unit, London, UK
975b
+
Sabrina Bakeera-Kitaka* 1 , Q Fillekes2 , R Keishanyu3 , N Young4 ,
A Babirye1 , C Tumusiime3 , L Kendall4 , M Lallemant5 , D Burger2 ,
and D Gibb4 1Baylor Coll of Med Children’s Fndn Uganda, Mulago Hosp, Kampala;;
2 3 Radboud Univ Nijmegen Med Ctr, Nijmegen, The Netherlands;; Joint
Clinical Res Ctr, Kampala, Uganda;; 4MRC Clinical Trials Unit, London,
UK;; and 5 983 Microarray Analysis Reveals Novel Insights into Immunity
to H1N1/09 Influenza Vaccine in HIV
Drugs for Neglected Diseases Initiative, Geneva, Switzerland
+ Children and
Adolescents in the International Maternal Pediatric
Savita Pahwa* 1 , L Trautmann2 , M Cameron2 , C Steel2 , R-P Sekaly2 ,
A Weinberg3 , C Cunningham4 , P Flynn5 , and IMPAACT P1088 Team
1 2 Univ of Miami Miller Sch of Med, FL, US;; Vaccine and Gene Therapy
Inst Florida, Port St Lucie, US;; 3Univ of Colorado Denver, US;; 4Duke Univ,
Durham, NC, US;; and 5 984 Higher Regulatory B and T Cell Rates Are Associated with
Decreased Immune Responses to pH1N1 Influenza Vaccine in
HIV + Children and Youth
Adriana Weinberg* 1 , P Muresan2 , T Fenton2 , K Richardson1 ,
T Dominguez1 , A Bloom3 , C Cunningham4 , S Spector5 , S Nachman6 ,
P Flynn7 , and IMPAACT P1088 Study Team
1 2 Univ of Colorado Denver, Aurora, US;; Harvard Sch of Publ Hlth,
Boston, MA, US;; 3Frontier Sci & Tech Res Fndn, Amherst, NY, US;; 4Duke Univ Med Ctr, Durham, NC, US;; 5Univ of California, San Diego, La
Jolla, US;; 6Stony Brook Hlth Sci Ctr, NY, US;; and 7 Hosp, Memphis, TN, US
976 Pharmacokinetics of Lopinavir/ritonavir Dosed According to
the WHO Pediatric Weight Band Dosing Guidelines: Interim
Jorge Pinto* 1 , E Capparelli 2 , M Mirochnick 3 , M Warshaw 4 , B Zimmer 5 ,
J Roa 6 , B Smith 7 , C Worrell 7 , T Cressey 8 , M Martinez-Tristani 9 ,
and IMPAACT P1083 Team
1 Univ Federal de Minas Gerais, Belo Horizonte, Brazil;; 2 Univ of
California, San Diego, US;; 3 Boston Med Ctr, MA, US;; 4 Harvard Sch of
Publ Hlth, Boston, MA, US;; 5 Frontier Sci & Tech Res Fndn, Buffalo, NY,
US;; 6 Social & Scientific Systems, Silver Spring, MD, US;; 7 NIH, Bethesda,
MD, US;; 8 Prgm for HIV Prevention and Treatment, Chiang Mai,
Thailand;; and 9 Abbott Labs, Miami, FL, US
c Wednesday, 2:30-4 pm; Hall B2
Session 182–Poster Abstracts
Response to Pediatric Vaccines in Children and
Youth
981 Human Papillomavirus Vaccination in ARV-treated HIV +
Adolescents and Young Adults Induces Strong Human
Papillomavirus-specific Cell-mediated Immune Responses
Daria Trabattoni* 1 , V Rainone 1 , F Penagini 2 , F Dinello 2 , F Calascibetta 1 ,
V Giacomet 2 , A Vigano 1,2 , M Clerici 1,3 , and GV Zuccotti 1,2
1 Univ of Milan;; 2 Luigi Sacco Hosp;; and 3 Don G Gnocchi Fndn
64 20th Conference on Retroviruses and Opportunistic Infections
c Monday, 2:30-4 pm; Hall B2
Session 183–Poster Abstracts
Preclinical Studies of Topical ARV for Prevention
977
+
Children in the Anti-
Retroviral Research for Watoto Trial
Victor Musiime* 1 , P Kasirye2 , B Naidoo-James3 , P Nahirya-Ntege4 ,
T Mhute5 , L Mugarura1 , M Munjoma5 , M Spyer3 , M Thomason3 ,
S Walker3 , and ARROW Trial Team
1 2 Joint Clinical Res Ctr, Kampala, Uganda;; Baylor-Uganda, Paediatric
Infectious Diseases Clin, Mulago Hosp, Kampala;; 3MRC Clinical Trials
Unit, London, UK;; 4MRC/Uganda Res Unit on AIDS, Uganda Virus Res
Inst, Entebbe;; and 5Univ of Zimbabwe, Harare
978 Pharmacokinetics of Darunavir 800 mg with Ritonavir 100 mg
Once Daily in HIV + Adolescents and Young Adults
Jennifer King* 1 , R Hazra2 , A Wiznia3 , P Jean-Philipe4 , B Graham5 ,
P Britto6 , V Carey6 , E Acosta1 , R Yogev7 , and IMPAACT P1058A Team
1 2 Univ of Alabama at Birmingham, US;; Natl Inst of Child Hlth and
Human Devt, NIH, Bethesda, MD, US;; 3Jacobi Med Ctr, Bronx, NY,
US;; 4Henry M Jackson Fndn for the Advancement of Military Med, NIH,
Bethesda, MD, US;; 5Frontier Sci & Tech, Amherst, NY, US;; 6Harvard Sch of Publ Hlth, Boston, MA, US;; and 7Childrens Memorial Hosp,
Northwestern Univ Feinberg Sch of Med, Chicago, IL, US
979 Methylphenidate Concentrations and Dose Requirements in
HIV + and HIV Brookie Best* 1 , M Farhad2 , S Rossi1 , J Hodge3 , S Kapetanovic4 ,
E Capparelli1 , P Brouwers4 , G Siberry5 , E Smith6 , M Paul7 ,
and IMPAACT P1080
1 2 Univ of California, San Diego, US;; Harvard Sch of Publ Hlth, Boston,
MA, US;; 3Frontier Sci & Tech Res Fndn, Amherst, NY, US;; 4Natl Inst
of Mental Hlth, NIH, Rockville, MD, US;; 5Natl Inst of Child Hlth and
Human Devt, NIH, Bethesda, MD, US;; 6NIAID, NIH, Bethesda, MD, US;;
and 7Baylor Coll of Med, Houston, TX, US
c Wednesday, 2:30-4 pm; Hall B2
Session 181–Poster Abstracts
Immune Response to Perinatal HIV
980
Early in HIV +
Andrew Prendergast* 1,2,3 , B Chasekwa1 , S Rukobo1 , T Mupfudze1,2 ,
M Govha1 , K Mutasa1 , and J Humphrey1,2 1 2 Zvitambo Project, Harare, Zimbabwe;; Johns Hopkins Univ Bloomberg Sch
of Publ Hlth, Baltimore, MD, US;; and 3 985 Impact of Depo-Provera and Menstrual Cycle on Vaginal
Charles Dobard*, S Sharma, R West, A Martin, N Makarova, A Taylor,
J Mitchell, C-P Pau, and W Heneine
CDC, Atlanta, GA, US
986 A Novel Intravaginal Ring Design Releasing Tenofovir
Vaginal Target Cells in Macaques to Gel Dosing
James Smith*
Queen Mary Univ of London, UK
1 , R Rastogi2 , R Teller2 , P Srinivasan1 , C-P Pau1 ,
J McNicholl1 , M Hendry1 , P Mesquita3 , B Herold3 , and P Kiser2 1 2 3 CDC, Atlanta, GA, US;; Univ of Utah, Salt Lake City, US;; and Albert
Einstein Coll of Med, Bronx, NY, US
987 Differential Intracellular Retention of Drugs: A Tool for
Pedro Mesquita* 1 , M Kay2 , and B Herold1 1 2 Albert Einstein Coll of Med, Bronx, NY, US and Univ of Utah, Salt Lake
City, US
988
Implications for HIV Prevention
Julie Russo* 1 , L Wang1 , L Rohan1,2 , I McGowan1,2 , and C Dezzutti1,2 1 2
Univ of Pittsbugh,
PA, US
989
from HIV-1 Infection
Yanille Scott* 1 , K Whaley2 , and C Dezzutti1 1 2 Univ of Pittsburgh, PA, US and Mapp Biopharmaceutical Inc,
San Diego, CA, US
990
Semen Exposure in Women from HIV: Prevention Trials
Kerri Penrose* 1 , B Richardson2 , G Besson1 , B Harold3 , C Dezzutti1 ,
S Abdool Karim4 , J Mellors1 , U Parikh1 , and MTN Biomed Sci Working
Group and HPTN 035 Protocol Team
1 2 3 Univ of Pittsburgh, PA, US;; Univ of Washington, Seattle, US;; Albert
Einstein Coll of Med, New York, NY, US;; and 4Ctr for the AIDS Prgm of
Res in South Africa, Durban
c Tuesday, 2:30-4 pm; Hall B2
Session 184–Poster Abstracts
Non-human Primate Models of STI, PrEP, and
Vaccines
991 Co-infection with STI Chlamydia trachomatis and
Trichomonas vaginalis
Pigtail Macaques
Tara Henning* 1 , K Butler 1 , D Hanson 1 , D Garber 1 , E Secor 1 , J Papp 1 ,
H Caldwell 2 , G Sturdevant 2 , J McNicholl 1 , and E Kersh 1
1 CDC, Atlanta, GA, US and 2 Natl Inst of Allergy and Infectious Diseases,
Hamilton, MT, US
992
the Prophylactic Efficacy of Truvada in Pigtail Macaques
Jessica Radzio*
982
+
Pediatric and Adolescent Patients
George Varghese*, S Pallikkuth, S Andreansky, I Gonzalez, and S Pahwa
Univ of Miami Miller Sch of Med, FL, US
1 , K Hanley2 , J Mitchell1 , S Bachman1 , F Deyounks1 ,
W Heneine1 , and G Garcia-Lerma1 1 2 CDC, Atlanta, GA, US and Emory Univ, Atlanta, GA, US
993 Prophylactic Efficacy of Oral Truvada against a Tenofovir-
M-E Cong, J Mitchell, E Sweeney, S Bachman, D Hanson, W Heneine,
and Gerardo Garcia-Lerma*
CDC, Atlanta, GA, US